Thiotepa–fludarabine–treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial

Therapeutic options for patients with AML relapsing after allogeneic HCT range from chemotherapy or hypomethylating agents with or without donor lymphocyte infusions to a 2nd allogeneic HCT. Available data are based on retrospective single center or registry studies. The aim of this multicenter tria...

Descripción completa

Detalles Bibliográficos
Autores principales: Finke, Jürgen, Schmoor, Claudia, Stelljes, Matthias, Burchert, Andreas, Dreger, Peter, Hegenbart, Ute, Wagner-Drouet, Eva-Maria, Bornhäuser, Martin, Sohlbach, Kristina, Schub, Natalie, Reicherts, Christian, Kobbe, Guido, Glass, Bertram, Bertz, Hartmut, Grishina, Olga
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630110/
https://www.ncbi.nlm.nih.gov/pubmed/35982219
http://dx.doi.org/10.1038/s41409-022-01777-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630110/
https://www.ncbi.nlm.nih.gov/pubmed/35982219
http://dx.doi.org/10.1038/s41409-022-01777-5

Ejemplares similares